MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on January 23, 2008; DOI: 10.1124/mol.107.043679


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.107.043679v1
73/4/1141    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Parnas, M. L.
Right arrow Articles by Vaughan, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Parnas, M. L.
Right arrow Articles by Vaughan, R. A.


Received for publication November 20, 2007.
Revised January 21, 2008.
Accepted for publication January 22, 2008.

LABELING OF DOPAMINE TRANSPORTER TRANSMEMBRANE DOMAIN 1 WITH THE TROPANE LIGAND [125I]MFZ 2-24 IMPLICATES PROXIMITY OF COCAINE AND SUBSTRATE ACTIVE SITES

M. Laura Parnas 1, Jon D. Gaffaney 1, Mu Fa Zou 2, John R. Lever 3, Amy Hauck Newman 2, Roxanne A. Vaughan 1*

1 University of North Dakota School of Medicine and Health Sciences 2 National Institute on Drug Abuse Intramural Research Program 3 University of Missouri

* Address correspondence to: E-mail: rvaughan{at}medicine.nodak.edu

Abstract

The novel photoaffinity ligand N-[4-(4-azido-3-[125I]-iodophenyl)butyl]-2-{beta}carbomethoxy-3{beta}-(4-chlorophenyl) tropane ([125I]MFZ 2-24) was used to investigate the site for cocaine binding on the dopamine transporter (DAT). [125I]MFZ 2-24 irreversibly labeled both rat striatal and expressed human DAT with high affinity and appropriate pharmacological specificity. Tryptic proteolysis of [125I]MFZ 2-24 labeled DAT followed by epitope- specific immunoprecipitation demonstrated that the ligand becomes adducted almost exclusively to transmembrane domains (TMs) 1-2. Further localization of [125I]MFZ 2-24 incorporation achieved by proteolyzing labeled wild type and methionine mutant DATs with cyanogen bromide identified the sequence between residues 68-80 in TM1 as the ligand adduction site. This is in marked contrast to the previously identified attachment of the photoaffinity label [125I]RTI 82 in TM6. Because [125I]MFZ 2-24 and [125I]RTI 82 possess identical tropane pharmacophores and differ only in the placement of the reactive azido moieties, their distinct incorporation profiles identify the regions of the protein adjacent to different aspects of the cocaine molecule. These findings thus strongly support the direct interaction of cocaine on DAT with TM1 and TM6, both of which have been implicated by mutagenesis and homology to a bacterial leucine transporter as active sites for substrates. These results directly establish the proximity of TMs 1 and 6 in DAT and suggest that the mechanism of transport inhibition by cocaine involves close interactions with multiple regions of the substrate permeation pathway.


Key words: Dopamine, Biogenic Amine, Receptor binding studies, Cocaine


This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
V. Murthy, T. J. Martin, S. Kim, H. M. L. Davies, and S. R. Childers
In Vivo Characterization of a Novel Phenylisothiocyanate Tropane Analog at Monoamine Transporters in Rat Brain
J. Pharmacol. Exp. Ther., August 1, 2008; 326(2): 587 - 595.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics